← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksARWREarnings History
OverviewAnalysisPriceRevenueEarningsP/ERatiosDividendTargets

ARWR logoArrowhead Pharmaceuticals, Inc. (ARWR) Earnings History

Annual and quarterly earnings data from 1997 to 2025

TTM Net Income
-$301M
Net Loss
TTM EPS
$-2.11
Diluted
YoY EPS Growth
+99.8%
Excellent
Net Margin
-0.2%
Profitability
Operating Margin11.9%
Gross Margin97.1%
ROE-0.5%
ROA-0.1%
Highest Annual Net Income$68M (2019)
Highest Quarterly EPS$13.64 (Q4 2003)
Consecutive Profitable Years0 years
Q2 2026
Net Income-$133M
EPS$-0.93
QoQ Growth-530.8%Declining

Loading earnings history...

ARWR EPS Growth (CAGR)

Compound annual growth rate of diluted earnings per share

1-Year
N/A
N/M
3-Year
N/A
N/M
5-Year
N/A
N/M
10-Year
N/A
N/M

CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.

ARWR Profitability Analysis

Margin trends over time

View revenue breakdown →
YearGross MarginOperating MarginNet Margin
202597.1%11.9%-0.2%
2024-423.7%-16927.1%-16882.4%
202394.8%-85.2%-85.3%
202295.7%-73.4%-72.4%
20210.0%-107.8%-101.9%
Gross Margin = Gross Profit ÷ Revenue
Operating Margin = Operating Income ÷ Revenue
Net Margin = Net Income ÷ Revenue

Download Data

Export ARWR earnings history in CSV or JSON format

Free sign-in required to download data

Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings Overview

As of May 8, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) reported trailing twelve-month net income of -$301M, reflecting +99.8% year-over-year growth. The company earned $-2.11 per diluted share over the past four quarters, with a net profit margin of -0.2%.

Looking at the long-term picture, ARWR's historical earnings data spans multiple years. The company achieved its highest annual net income of $68M in fiscal 2019.

Arrowhead Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including ALNY ($577M net income, 8.4% margin), NTLA (-$413M net income, -609.9% margin), BEAM (-$65M net income, -57.2% margin), ARWR has room to improve margins relative to the peer group. Compare ARWR vs ALNY →

ARWR Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ARWR logoARWRCurrent
-$301M$-2.11-0.2%-0.5%+99.8%—
ALNY logoALNY
$577M$4.188.4%73.3%+206.9%
NTLA logoNTLA
-$413M$-3.81-609.9%-53.5%+27.4%
BEAM logoBEAM
-$65M$-0.63-57.2%-8.1%+82.3%
SRPT logoSRPT
$65M$0.53-32.5%-53.5%-404.7%
IONS logoIONS
-$327M$-1.98-40.4%-70.7%+21.7%
Best in group
Lowest in group

ARWR Historical Earnings Data (1997–2025)

29 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$2M+99.7%$98M$-0.01-0.2%11.9%
2024-$599M-192.0%-$601M$-5.00-16882.4%-16927.1%
2023-$205M-16.6%-$205M$-1.92-85.3%-85.2%
2022-$176M-25.0%-$179M$-1.67-72.4%-73.4%
2021-$141M-66.6%-$149M$-1.36-101.9%-107.8%
2020-$85M-224.4%-$93M$-0.84-96.1%-105.9%
2019$68M+224.8%$61M$0.6940.3%36.3%
2018-$54M-58.4%-$56M$-0.65-337.3%-346.5%
2017-$34M+57.9%-$37M$-0.47-109.5%-117.8%
2016-$82M+11.1%-$82M$-1.34-51614.6%-51627.1%

Full ARWR Stock Analysis

Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.

View Analysis

See ARWR's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is ARWR Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare ARWR vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

ARWR — Frequently Asked Questions

Quick answers to the most common questions about buying ARWR stock.

Is ARWR growing earnings?

ARWR EPS is $-2.11, with earnings growth accelerating to +99.8%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-301M.

What are ARWR's profit margins?

Arrowhead Pharmaceuticals, Inc. net margin is -0.2%, with operating margin at +11.9%. Below-average margins reflect competitive or cost pressures.

How consistent are ARWR's earnings?

ARWR earnings data spans 1997-2025. The accelerating earnings trend is +99.8% YoY. Historical data enables comparison across business cycles.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

ARWR Earnings Over Time (2014–2025)

Net income and EPS trends